Tirzepatide denied for failing step therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for tirzepatide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Applies Step Therapy to Tirzepatide

Step-therapy (also called "fail-first") denials require you to try and fail one or more less expensive or preferred medications before the plan will cover tirzepatide. BCBS's step-therapy protocol for tirzepatide is defined in its coverage policy and will specify which agents must be tried, in what order, and for what duration. This denial is common and routinely overturned when the required prior steps are already documented in the chart — or when a clinical exception applies.

Many states have step-therapy protection laws that limit how insurers can apply these requirements, especially when a prescriber documents that the required prior drug is contraindicated, ineffective, or likely to cause harm. Check your state's step-therapy laws in addition to pursuing the federal appeal process.

## Your Federal Appeal Rights

Under ACA §2719 and ERISA §503, you have a right to internal appeal and independent external review. Internal appeal deadlines are typically 180 days from the denial notice. External review is generally available for approximately 4 months after final internal denial. Request expedited review if a delay in treatment poses an urgent health risk.

## Concrete Appeal Steps

1. Obtain the denial letter identifying which step-therapy requirements were not satisfied. 2. Request BCBS's full step-therapy protocol for tirzepatide — the specific prior-agent requirements must be disclosed. 3. Audit the chart for prior use of any required agents: dates initiated, duration, doses (from the chart), and the documented reason for discontinuation or switch. 4. If prior steps are already satisfied, submit documentation showing this; the denial should be reversed. 5. If prior steps are not yet satisfied, have your prescriber evaluate whether a clinical exception applies (e.g., prior agent contraindicated, prior agent caused adverse effects, clinical urgency). 6. File a formal internal appeal with the full clinical package and request external review if denied.

## Documentation to Gather

• Medication history: a complete, dated list of all prior weight-management or relevant chronic-disease agents tried, with durations and outcomes
• Discontinuation records: chart notes documenting why each prior agent was stopped (intolerance, inadequate response, contraindication)
• Prescriber medical-necessity letter: explicitly addresses each required step, confirms which are satisfied, and explains any exception basis
• Relevant guideline reference: the applicable ADA, AACE/ACE, or Obesity Medicine Association guideline supports individualized prescribing decisions — your prescriber should cite this

## Criteria-Mapping Structure

List each required step from BCBS's protocol in a table. For each step: (1) was it completed — yes/no; (2) if yes, the date, agent, duration, and documented outcome; (3) if no, the clinical reason it cannot or should not be completed. This structure directly answers every criterion the plan's medical reviewer will check.